The efficacy of combination therapy was documented in a case report of a DLBCL patient whose disease progression after receiving CD19-targeted CAR-T cell therapy (4-1BB/CD3-ζ) [98]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.